PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer

Huaqiang Zhou; Jiaqing Liu; Yaxiong Zhang; Yan Huang; Jiayi Shen; Yunpeng Yang; Wenfeng Fang; Li Zhang

doi:10.1038/s41698-020-0112-3

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer

NPJ Precis Oncol. 2020 Mar 16:4:6. doi: 10.1038/s41698-020-0112-3. eCollection 2020.

Authors

Huaqiang Zhou^#^{1

2

3}, Jiaqing Liu^#^{1

2

3

4}, Yaxiong Zhang^#^{1

2

3}, Yan Huang^#^{1

2

3}, Jiayi Shen^#⁴, Yunpeng Yang^{1

2

3}, Wenfeng Fang^{1

2

3}, Li Zhang^{1

2

3}

Affiliations

¹ 1Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
² 2State Key Laboratory of Oncology in South China, Guangzhou, China.
³ Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
⁴ 4Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.

^# Contributed equally.

Abstract

Polybromo-1 (PBRM1) gene is a promising biomarker for immunotherapy in clear cell renal cell carcinoma. But to our knowledge, the frequency and clinical relevance of PBRM1 mutation in lung cancer remain unknown. We conducted a retrospective study to evaluate the prevalence of PBRM1 mutation and its correlation with preliminary response to immunotherapy in non-small cell lung cancer (NSCLC). Our results indicated that PBRM1 mutation was more likely to be a negative predictive biomarker for immunotherapy in NSCLC.

Keywords: Cancer genomics; Non-small-cell lung cancer; Predictive markers.